We’re just out of the gate of a new month and, like always in the Dividends & Income Daily world, that means it’s time to roll out another round of Dividend Stock Wars.
This time, I’m putting Pfizer (PFE) up against Bristol-Myers Squibb (BMY).
~Round 1: Simple Business
The rule is easy: The simpler the business, the better the investment.
This holds especially true for income investing. The fewer the moving parts, the fewer the risks – and the more likely you’ll be getting that dividend next quarter (and the next, and the next).
Unfortunately, Big Pharma is anything but simple.
Click here to continue reading…
The post Dividend Drug Wars: Pfizer vs. Bristol-Myers Squibb appeared first on Wall Street Daily.
Article By WallStreetDaily.com
Original Article: Dividend Drug Wars: Pfizer vs. Bristol-Myers Squibb
